Retractable Tech | 10-Q: FY2025 Q3 Revenue: USD 10.09 M

Revenue: As of FY2025 Q3, the actual value is USD 10.09 M.

EPS: As of FY2025 Q3, the actual value is USD 0.01.

EBIT: As of FY2025 Q3, the actual value is USD -3.781 M.

Total Sales: $10,085,723 for the three months ended September 30, 2025, compared to $10,346,857 for the same period in 2024. For the nine months ended September 30, 2025, total sales were $28,826,629, compared to $23,975,584 for the same period in 2024.
U.S. Sales: $9,187,576 for the three months ended September 30, 2025, compared to $9,628,608 for the same period in 2024. For the nine months ended September 30, 2025, U.S. sales were $25,109,563, compared to $21,283,346 for the same period in 2024.
North and South America Sales (excluding U.S.): $549,798 for the three months ended September 30, 2025, compared to $569,970 for the same period in 2024. For the nine months ended September 30, 2025, sales were $2,848,734, compared to $1,390,883 for the same period in 2024.
Other International Sales: $348,349 for the three months ended September 30, 2025, compared to $148,279 for the same period in 2024. For the nine months ended September 30, 2025, sales were $868,332, compared to $1,301,355 for the same period in 2024.

Net Income (Loss): Net income of $371,047 for the three months ended September 30, 2025, compared to a net loss of - $1,921,989 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $10,217,140, compared to - $15,657,246 for the same period in 2024.
Gross Profit (Loss): Gross profit of $1,685,904 for the three months ended September 30, 2025, compared to a gross loss of - $14,810 for the same period in 2024. For the nine months ended September 30, 2025, gross profit was $1,576,903, compared to $1,466,195 for the same period in 2024.
Operating Expenses: $5,339,946 for the three months ended September 30, 2025, compared to $5,120,934 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $15,038,535, compared to $15,350,882 for the same period in 2024.
Loss from Operations: - $3,654,042 for the three months ended September 30, 2025, compared to - $5,135,744 for the same period in 2024. For the nine months ended September 30, 2025, loss from operations was - $13,461,632, compared to - $13,884,687 for the same period in 2024.

Operating Cash Flow: Cash flow used by operations was - $6,467,836 for the nine months ended September 30, 2025, compared to - $10,452,299 for the same period in 2024.
Investing Cash Flow: Cash flow from investing activities was $6,099,634 for the nine months ended September 30, 2025, compared to $2,100,432 for the same period in 2024.
Financing Cash Flow: Cash used by financing activities was - $422,648 for the nine months ended September 30, 2025, compared to - $398,437 for the same period in 2024.

Unrealized Gain (Loss) on Debt and Equity Securities: Unrealized gain of $2,383,779 for the three months ended September 30, 2025, compared to $1,449,825 for the same period in 2024. For the nine months ended September 30, 2025, unrealized loss was - $3,217,058, compared to $1,402,660 for the same period in 2024.
Litigation Proceeds: $1,900,000 received in May 2025 related to the resolution of litigation with former legal counsel.

Core Business Focus: The company plans to increase domestic manufacturing capabilities to reduce reliance on imports and mitigate the impact of tariffs. This includes adapting equipment to produce 0.5 mL syringes domestically, with commercial quantities expected to be available in the first half of 2026.
Non-Core Business: The company is working to lessen the financial impact of tariffs through strategic ordering of products from Chinese suppliers and shifting a larger portion of manufacturing to its domestic facility. This shift is expected to increase manufacturing workforce costs by approximately $825,000 on an annualized basis.
Priority: The company expects to meet its short-term liquidity needs for at least 12 months from the date of issuance of the financial statements, using cash reserves, expected income from operations, and investments in trading securities if necessary.